Raxibacumab

Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA) . Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research[1][2].

Product Specifications

CAS Number

[565451-13-0]

Product Name Alternative

ABthrax

UNSPSC

12352203

Target

Bacterial

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/raxibacumab.html

Purity

98.88

Solubility

H2O

Smiles

[Raxibacumab]

Molecular Weight

(142.96 kDa)

References & Citations

[1]Mazumdar S. Raxibacumab. MAbs.2009 Nov-Dec;1 (6) :531-8. |[2]Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist. 2014 Apr 29;7:101-9. |[3]Cui X, et.al. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis. 2005 Feb 1;191 (3) :422-34.